<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00908154</url>
  </required_header>
  <id_info>
    <org_study_id>107727</org_study_id>
    <secondary_id>SCB107727</secondary_id>
    <nct_id>NCT00908154</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802.</brief_title>
  <official_title>Single-blind, Randomised, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Repeat Doses of GSK1014802 and Its Interaction With Food in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <brief_summary>
    <textblock>
      GSK1014802 is a use-dependent sodium channel blocker and an effective anticonvulsant in&#xD;
      animal models.&#xD;
&#xD;
      This study is being conducted to obtain information regarding the safety, tolerability and&#xD;
      pharmacokinetics of repeated doses of GSK1014802 administered for up to 28 days in healthy&#xD;
      male or female subjects. In addition, the effect of food on the pharmacokinetics of&#xD;
      GSK1014802 will be investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study, previously posted by GlaxoSmithKline (GSK), was transitioned to Convergence&#xD;
      Pharmaceuticals, Ltd., which spun off from GSK. Convergence Pharmaceuticals, Ltd., has now&#xD;
      been acquired by Biogen.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2008</start_date>
  <completion_date type="Actual">December 31, 2008</completion_date>
  <primary_completion_date type="Actual">December 31, 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability will be evaluated by monitoring AEs and concomitant medication, ECG, Lead II monitoring, Holter monitoring, vital signs, and laboratory parameters.</measure>
    <time_frame>14-28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood concentrations of GSK1014802 following a single oral dose of GSK1014802.</measure>
    <time_frame>1 day</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood concentrations of GSK1014802 following repeated oral doses of GSK1014802 given once daily or twice daily and their relationship with the GSK1014802 exposure after a single dose.</measure>
    <time_frame>14-28 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood concentrations of GSK1014802 following repeated oral doses of GSK1014802 given once daily with or without food.</measure>
    <time_frame>14-28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bond-Lader VAS scale</measure>
    <time_frame>14-28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Bipolar Depression</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Tablets to match GSK1014802</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1014802</intervention_name>
    <description>Sodium channel blocker</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <other_name>BIIB074 and CNV1014802</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy as determined by a responsible physician, based on a medical evaluation&#xD;
             including medical history, physical examination, laboratory tests and cardiac&#xD;
             monitoring.&#xD;
&#xD;
               -  Male or female (of non-child bearing potential) subjects aged between 18 and 55&#xD;
                  years.&#xD;
&#xD;
               -  A female subject is eligible to participate if she is of non-childbearing&#xD;
                  potential.&#xD;
&#xD;
               -  Male subjects must agree to use an acceptable form of contraception.&#xD;
&#xD;
               -  Body weight â‰¥ 50 kg and BMI within the range 19 - 29.9 kg/m2 (inclusive)&#xD;
&#xD;
               -  Capable of giving written informed consent, which includes compliance with the&#xD;
                  requirements and restrictions listed in the consent form.&#xD;
&#xD;
               -  QTcB or QTcF &lt; 450 msec; or QTc &lt; 480 msec in subjects with Bundle Branch Block.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  The subject has a positive pre-study drug/alcohol screen.&#xD;
&#xD;
               -  A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody&#xD;
                  result within 3 months of screening&#xD;
&#xD;
               -  A positive test for HIV antibody.&#xD;
&#xD;
               -  History of regular alcohol consumption within 6 months of the study defined as an&#xD;
                  average weekly intake of greater than 21 units or an average daily intake of&#xD;
                  greater than 3 units (males), or defined as an average weekly intake of greater&#xD;
                  than 14 units or an average daily intake of greater than 2 units (females).&#xD;
&#xD;
               -  Current or past history of symptomatic orthostatic hypotension or history of&#xD;
                  unexplained vasovagal episode(s).&#xD;
&#xD;
               -  The subject has participated in a clinical trial and has received an&#xD;
                  investigational product within the following time period prior to the first&#xD;
                  dosing day in the current study: 30 days, 5 half-lives (60 h) or twice the&#xD;
                  duration of the biological effect of the investigational product (whichever is&#xD;
                  longer).&#xD;
&#xD;
               -  Exposure to more than four new chemical entities within 12 months prior to the&#xD;
                  first dosing day.&#xD;
&#xD;
               -  Use of prescription or non-prescription drugs, including vitamins, herbal and&#xD;
                  dietary supplements (including St John's Wort) within 7 days (or 14 days if the&#xD;
                  drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior&#xD;
                  to the first dose of study medication.&#xD;
&#xD;
               -  History of sensitivity to any of the study medications, or components thereof or&#xD;
                  a history of drug or other allergy that, in the opinion of the investigator or&#xD;
                  GSK Medical Monitor, contraindicates their participation.&#xD;
&#xD;
               -  Where participation in the study would result in donation of blood or blood&#xD;
                  products in excess of 500 mL within a 56 day period.&#xD;
&#xD;
               -  Pregnant females.&#xD;
&#xD;
               -  Lactating females.&#xD;
&#xD;
               -  Unwillingness or inability to follow the procedures outlined in the protocol.&#xD;
&#xD;
               -  History of sensitivity to heparin or heparin-induced thrombocytopenia.&#xD;
&#xD;
               -  Urinary cotinine levels indicative of smoking or history or regular use of&#xD;
                  tobacco- or nicotine-containing products within 6 months prior to screening.&#xD;
&#xD;
               -  . Consumption of red wine, seville oranges, grapefruit or grapefruit juice and/or&#xD;
                  pummelos, exotic citrus fruits, grapefruit hybrids or fruit juices from 7 days&#xD;
                  prior to the first dose of study medication.&#xD;
&#xD;
               -  History of known or suspected seizures, including infantile febrile, unexplained&#xD;
                  significant and recent loss of consciousness or history of significant head&#xD;
                  trauma with loss of consciousness or a family history (first degree relative) of&#xD;
                  epilepsy or seizures (fits).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Biogen Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SE1 1YR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <study_first_submitted>May 7, 2009</study_first_submitted>
  <study_first_submitted_qc>May 21, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2009</study_first_posted>
  <last_update_submitted>October 27, 2017</last_update_submitted>
  <last_update_submitted_qc>October 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 30, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sodium channel blocker</keyword>
  <keyword>bipolar disorder</keyword>
  <keyword>repeat dose</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

